On the Prostate Problems Mailing List there has been some recent discussion and a large amount of confusion expressed about the need for and importance of surrogate end points for drug and treatment approval. I attempted to make a very simple clarification and recommendation about surrogates. Here it is, but slightly modified ……. Maybe I [...]
At the European Association of Urology’s 23rd Annual Congress there was an abstract presented (Abstract 186) that concluded that three-dimensional external beam radiation (EBRT) with 6 months of androgen deprivation therapy (ADT) for the treatment of patients with locally advanced prostate cancer shows significantly shorter patient survival than the same treatment followed by 3 years [...]
Gynecomastica is a taboo subject with many men. Men have a hard enough time talking about prostate cancer, but discussing their breast growth is just too much for many. However, many of us who are treated for prostate cancer experience breast growth, gynecomastica. Despite how difficult it is to discuss it, gynecomastica is one of [...]
A recent announcement about the once daily oral drug abiraterone acetate (CB7630) indicated that some of the current trial results demonstrate some efficacy in men with hormone refractory prostate cancer. The positive results appeared at two different stages of the standard treatment process. Positive results were demonstrated both before and after the administration of chemotherapy. [...]
Many of us think that chemotherapy for prostate cancer only involves the use of Taxotere. Just for the sake of accuracy, I want to clarify that almost every drug we take to treat prostate cancer is chemotherapy. Chemotherapy drugs are the drugs that are designed to kill cells. All of the drugs used as a [...]